My presentation at the E-cigarette Summit Washington DC, 30 April 2018. "The urge to ban: 10 questions to ask first" calling for calm over flavors and the latest moral panic over JUUL.
Regulation: why less is more... E-cigarette Summit 12 November 2013 - Clive B...Clive Bates
My presentation covering why 'less is more' when it comes to regulating low risk alternatives to cigarettes such as e-cigarettes. Too much regulation will limit appeal, increase costs, raise barriers to entry and inhibit innovation. I also urge a focus on the huge potential benefits of low-risk alternatives to smoking instead of obsession over minor or implausible risks.
Nicotina - Reducción de riesgos y daños / Nicotine - Risk and Harm ReductionClive Bates
Presentación en línea para el seminario de políticas en Colombia enfocado en políticas de vapeo y consecuencias no deseadas /
Presentation online for policy seminar in Colombia focussed on vaping policy and unintended consequences
Regulation: why less is more... E-cigarette Summit 12 November 2013 - Clive B...Clive Bates
My presentation covering why 'less is more' when it comes to regulating low risk alternatives to cigarettes such as e-cigarettes. Too much regulation will limit appeal, increase costs, raise barriers to entry and inhibit innovation. I also urge a focus on the huge potential benefits of low-risk alternatives to smoking instead of obsession over minor or implausible risks.
Nicotina - Reducción de riesgos y daños / Nicotine - Risk and Harm ReductionClive Bates
Presentación en línea para el seminario de políticas en Colombia enfocado en políticas de vapeo y consecuencias no deseadas /
Presentation online for policy seminar in Colombia focussed on vaping policy and unintended consequences
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...Clive Bates
Clive Bates presentation at a seminar in the European Parliament organised by Monika Beňová MEP
European Commission DG SANTE - Matus Ferech
Patient Access Partnership - Dr. Stanimir Hasurdjiev
Vaping and tobacco: six things you need to know about harm reductionClive Bates
1. Smoking has not gone away
2. Technologies to obsolete cigarettes
3. Risks and risk (mis)perceptions
4. The public health mechanism and the pleasure principle
5. The youth vaping epidemic – a harder look
6. Policymaking and perverse consequences
Is nicotine reduction a viable policy for tobacco control? No, Definitely not...Clive Bates
My critique of the proposal that regulators should reduce the concentration of nicotine in cigarettes to a sub-addictive level - effectively a prohibition of cigarettes as we know them.
Presentation at SRNT 2017 in Florence, Italy on 8 March 2017.
Competent or careless? Directions in European policy on low-risk nicotine pr...Clive Bates
Presentation to ENDS conference, 20 April 2021.
Discussion of (1) the threat posed by upcoming EU regulatory developments on tobacco/nicotine; (2) the importance of understanding the underlying public health model; (3) the danger of perverse unintended consequences; (4) the adolescent vaping narrative and what is wrong with it; (5) the proactive alternative - risk-proportionate regulation.
E-cigarette Summit - The New Tobacco Wars - 7 December 2021Clive Bates
The presentation gives my take on the conflict raging in tobacco control. It looks at where things are going wrong in science, risk communication, policy, and youth politics. It then looks at causes: institutional and cultural inertia. And finally, finds hope in the basic processes of innovation.
Reduced nicotine rule: a terrible idea to be pursued relentlesslyClive Bates
Presentation to FDLI conference 26th October 2017. For more information and full report see: https://www.clivebates.com/fda-wants-to-reduce-nicotine-in-cigarettes-what-could-possibly-go-wrong-and-right/
The MRTP process - Seven provocations - FDLI webinar 30 July 2020Clive Bates
My presentation for a Food and Drug Law Institute webinar on the FDA's Modified Risk Tobacco Product process for making risk-related claims about tobacco and nicotine products
NYU College of Global Health - E-cigarette seminar - New YorkClive Bates
E-Cigarettes: The Tectonic Shift in Nicotine and Tobacco Consumption: Opportunity or Threat to Saving Lives?
Clive Bates
Friday, October 19, 2018
NYU School of Law, Greenberg Lounge
40 Washington Square South, New York, New York
Seven insights into tobacco harm reductionClive Bates
1st Tobacco Harm Reduction Malaysia Scientific Meeting
21 November 2021.
1. The problem is smoking
2. Smoke-free alternatives
3. Quitting smoking with smoke-free alternatives
4. Health concerns
5. Youth vaping
6. Policy and unintended consequences
7. Innovation (and its enemies)
FDLI - Lesson for the US from other jurisdictions - the United Kingdom -29 Oc...Clive Bates
Presentation on the most significant differences between US and UK/EU regulation of tobacco and vaping products. FDLI Tobacco and Nicotine Products Regulation and Policy Conference
Innovation for Consumers: E-cigarettes and novel tobacco products - Part of t...Clive Bates
Clive Bates presentation at a seminar in the European Parliament organised by Monika Beňová MEP
European Commission DG SANTE - Matus Ferech
Patient Access Partnership - Dr. Stanimir Hasurdjiev
Vaping and tobacco: six things you need to know about harm reductionClive Bates
1. Smoking has not gone away
2. Technologies to obsolete cigarettes
3. Risks and risk (mis)perceptions
4. The public health mechanism and the pleasure principle
5. The youth vaping epidemic – a harder look
6. Policymaking and perverse consequences
Is nicotine reduction a viable policy for tobacco control? No, Definitely not...Clive Bates
My critique of the proposal that regulators should reduce the concentration of nicotine in cigarettes to a sub-addictive level - effectively a prohibition of cigarettes as we know them.
Presentation at SRNT 2017 in Florence, Italy on 8 March 2017.
Competent or careless? Directions in European policy on low-risk nicotine pr...Clive Bates
Presentation to ENDS conference, 20 April 2021.
Discussion of (1) the threat posed by upcoming EU regulatory developments on tobacco/nicotine; (2) the importance of understanding the underlying public health model; (3) the danger of perverse unintended consequences; (4) the adolescent vaping narrative and what is wrong with it; (5) the proactive alternative - risk-proportionate regulation.
E-cigarette Summit - The New Tobacco Wars - 7 December 2021Clive Bates
The presentation gives my take on the conflict raging in tobacco control. It looks at where things are going wrong in science, risk communication, policy, and youth politics. It then looks at causes: institutional and cultural inertia. And finally, finds hope in the basic processes of innovation.
Reduced nicotine rule: a terrible idea to be pursued relentlesslyClive Bates
Presentation to FDLI conference 26th October 2017. For more information and full report see: https://www.clivebates.com/fda-wants-to-reduce-nicotine-in-cigarettes-what-could-possibly-go-wrong-and-right/
The MRTP process - Seven provocations - FDLI webinar 30 July 2020Clive Bates
My presentation for a Food and Drug Law Institute webinar on the FDA's Modified Risk Tobacco Product process for making risk-related claims about tobacco and nicotine products
NYU College of Global Health - E-cigarette seminar - New YorkClive Bates
E-Cigarettes: The Tectonic Shift in Nicotine and Tobacco Consumption: Opportunity or Threat to Saving Lives?
Clive Bates
Friday, October 19, 2018
NYU School of Law, Greenberg Lounge
40 Washington Square South, New York, New York
Seven insights into tobacco harm reductionClive Bates
1st Tobacco Harm Reduction Malaysia Scientific Meeting
21 November 2021.
1. The problem is smoking
2. Smoke-free alternatives
3. Quitting smoking with smoke-free alternatives
4. Health concerns
5. Youth vaping
6. Policy and unintended consequences
7. Innovation (and its enemies)
FDLI - Lesson for the US from other jurisdictions - the United Kingdom -29 Oc...Clive Bates
Presentation on the most significant differences between US and UK/EU regulation of tobacco and vaping products. FDLI Tobacco and Nicotine Products Regulation and Policy Conference
Circles of San Antonio Community Coalition Staff conducted a presentation for the Prevention Resource Center, Region 8 on why Alcohol is the # 1 drug of concern in San Antonio and Texas.
12 GLOBAL PROVEN WAYS ON HOW TO STOP ADDICTIONSTanimola Samuel
12 PROVEN WAYS ON HOW TO STOP ADDICTIONS
Stopping or quitting an addiction is never an easy job or a simple procedure. It necessarily requires determined effort, and effort.
There are however 12 proven ways for anyone in the world on how to stop addictions. If you will adhere to them to the letter, they can greatly assist you in overcoming any addiction you may have.
Get all the tools you’ll need to solve your addictions right now!
Take into account a cigar, a swig of whiskey, a giggle of cocaine, a slip of narcotics, or a hit of marijuana. Put aside the question not on whether narcotics are legitimate.
Focus solely on the structure for the time being. Trillions of powerful molecules pass across your blood before hitting your brain the time you leave that puff, a certain slug, that swallow, that shot, that puff.
These substances will cause a chain reaction of electrical and chemical events that will bounce through your skull and reorganize your mind’s inner reality after they have settled there. You’ll be hooked once you recognize it.
Everyone has their own addictions in this country. When your addictions go too far, you will know it’s necessary to end them before they seize control of your life and you hit the dead end.
11 MOST COMMON EXPERIENCED ADDICTIONS THAT PEOPLE FOUND DIFFICULT TO STOP IN ...Tanimola Samuel
11 MOST COMMON EXPERIENCED ADDICTIONS THAT PEOPLE FOUND DIFFICULT TO STOP IN THEIR LIVES
Addiction affects one out of every eight people. Our list of the 11 most popular addictions is as follows:
1• Video game addiction: Addiction to video games is common in both younger and older people, and it can harm family and mental health. However, according to experts, about 10% of players suffer from habitual addiction.
2. Web or Social Media addiction: People who are addicted to technology and social media spend a lot of their time on their computers or phones linked to the Web....
Similar to E-cigarette Summit US presentation 2018 (8)
FDLI Annual 2024: seven reasons why the litigation will never stopClive Bates
I give seven reaons underpinning the conflicts between FDA and vape companies...
1. Evidential burdens
2. Opaque success criteria
3. Defining APPH
4. Naivety about youth
5. De facto standard setting
6. Assessing products in isolation
7. Poor market surveillance
US E-cigarette Summit: Taming the nicotine industrial complexClive Bates
I look back to 1997 and simpler time in tobacco control, then look at changes in trade, communications, technology and conclude the market is becoming ungovernable
The end of what? UK E-cigarette Summit 2023Clive Bates
The extended version of my presentation to the UK E-cigarette summit 16 November 2023. We look at the following:
1. End of harm or end of nicotine
2. The demand for nicotine
3. The future market for nicotine
4. False risk perceptions
5. Who is to blame
The APPH Standard: What Does it Actually Mean?Clive Bates
My presentation at the Food & Drug Law Institute Tobacco and Nicotine conference 26 October 2023. I discuss five problems with the APPH concept:
1. No means of trading off different types of benefits and detriments
2. Ignores vaping benefits to youth
3. Blind to harmful unintended consequences of marketing denial orders
4. Impossible to estimate population effects at the product level - the standard only makes sense at the category level.
5. The aggregate effect of thousands of single product PMTA determinations may create adverse effects not captured in any individual application (de fact flavour ban)
I finish with three broad proposals:
1. Assess individual risk and marketing strategy pre-market
2. Assess population effects when it is actually possible to observe them - post-market
3. Conduct a single comprehensive market assessment covering all products, including illicit trade
Rethinking nicotine: illusions, delusions and some conclusionsClive Bates
presentation to the UK E-cigarette Summit on 9 December 2022. Looks at how our approach to nicotine must evolve from a "tobacco harm reduction" to treating nicotine like a socially acceptable recreational stimulant with minimal harm.
African Harm Reduction Exchange - Dec 2022Clive Bates
The science behind Tobacco Harm Reduction …and how it impacts policy development and regulation
1. Smoking is the main problem
2. Smokefree products and science
3. Policy and unintended consequences
4. Innovation (and its enemies)
Barriers and unintended consequences How poor regulation of low-risk alternat...Clive Bates
A shirt presentation to Georgian health experts on the dangers of excessive regulation of safer alternatives to smoking causing perverse unintended consequences.
10 provocations on why FDA's regulation of tobacco and nicotine is failing the American public. My presentation to the US E-cigarette Summit 2022 in Washington DC, with bonus content of additional background slides added in.
India - Economic Times - Consumer Freedom Conclave - 24 Feb 2022Clive Bates
Tobacco harm reduction: the biggest public health win of the 21st Century?
1. Tobacco harm reduction
2. Risk communication
3. Policymaking
4. Cause of opposition
5. Innovation
Albania National Association of Public health - Harm Reduction ConferenceClive Bates
Seven insights into tobacco harm reduction (20 min version) 20th December 2021.
1.The problem is smoking
2. Smoke-free alternatives
3. Quitting smoking with smoke-free alternatives
4. Health concerns
5. Youth vaping
6. Policy and unintended consequences
7. Innovation (and its enemies)
Effects of alternative nicotine delivery systems on cigarette consumption and...Clive Bates
Presentation at SRNT-Europe Conference September 2019 on the impact of vaping and other reduced-risk products on cigarette sales and smoking prevalence.
To see the fully animated version, please download.
Regulation of Tobacco Harm Reduction - GFN 2018 ScholarsClive Bates
Global Forum on Nicotine 2018 Scholars meeting on regulation discusses optimum regulation using 4 Ps of marketing framework to consider risk-proportionate regulation
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
1. The urge to ban: 10 questions to ask first
E-cigarette Summit U.S. 2018
30th April 2018
Washington DC
Clive Bates
Counterfactual
London
www.clivebates.com
3. 2. Chemical, flavor or descriptor?
3
1. Combustible or not?
2. Chemical, flavor or descriptor?
4. 3. What are the flavors of concern?
4
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
I have real concerns about
kids’ use of e-cigarettes […]
especially those products
marketed with obviously
kid-appealing flavors.
Scott Gottlieb, FDA
5. 3. What are the flavors of concers?
5
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
Shiffman S, Sembower MA, Pillitteri JL, Gerlach KK, Gitchell JG. The impact of flavor descriptors on
nonsmoking teens’ and adult smokers' interest in electronic cigarettes. Nicotine Tob Res 2015
Participants indicated their interest (0-10 scale) in e-cigarettes paired with various flavor descriptors
6. 4. Is use among adolescents similar to adults?
6
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
55% share
7. 5. What is the behavior of concern?
7
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
8. 6. Does a flavor preference create a change in behavior?
8
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
9. Ambrose et al, JAMA, 2015
7. Is the behavior change harmful or beneficial?
9
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
7. Is the behavior change harmful or beneficial to health?
10. 8. Trade-offs between harms and benefits to youth?
10
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
7. Is the behavior change harmful or beneficial to health?
8. Trade-offs between harms and benefits to youth?
11. 9. Benefits to adults versus any net harm to youth?
11
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
7. Is the behavior change harmful or beneficial to health?
8. Trade-offs between harms and benefits to youth?
9. Benefits to adults versus any net harm youth?
Less than a
quarter use
tobacco flavours
12. 9. Benefits to adults versus any net harm to youth?
12
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
7. Is the behavior change harmful or beneficial to health?
8. Trade-offs between harms and benefits to youth?
9. Benefits to adults versus any net harm youth?
About three-
quarters relied
fully or partially
on flavours
13. 9. Benefits to adults versus any net harm to youth?
13
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
7. Is the behavior change harmful or beneficial to health?
8. Trade-offs between harms and benefits to youth?
9. Benefits to adults versus any net harm youth?
14. 9. Benefits to adults versus any net harm to youth?
14
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
7. Is the behavior change harmful or beneficial to health?
8. Trade-offs between harms and benefits to youth?
9. Benefits to adults versus any net harm youth?
But now the U.S. tobacco market
is beginning to be disrupted by
JUUL — U.S. cigarette volumes fell
6% in 1Q18 according to Nielsen,
about 1-2% worse than historic
models would suggest. This is due
to the rapid growth of JUUL.
Adam Spielman - Citi April 2018
15. 10. Impact of FDA rule-making and unintended consquences?
15
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
7. Is the behavior change harmful or beneficial to health?
8. Trade-offs between harms and benefits to youth?
9. Benefits to adults versus any net harm youth?
10. Impact of FDA rule-making and unintended consequences?
Use other
Mix own and sell
Buy from China online
Smoke cigarettes
Marijuana, Meth, Fentanyl
That’s a
good boy
FDA bans some
flavors or Juul
Now what?
Total
abstinence?
N
Y
16. The urge to ban: 10 questions to ask first
1. Combustible or not?
2. Chemical, flavor or descriptor?
3. What are the flavors of concern?
4. Is use among adolescents similar to adults?
5. What is the behavior of concern?
6. Does a flavor preference create a change in behavior?
7. Is the behavior change harmful or beneficial to health?
8. Trade-offs between harms and benefits to youth?
9. Benefits to adults versus any net harm youth?
10. Impact of FDA rule-making and unintended consequences?